Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.

Merck Makes Deal Worth at Least $600 Million With Santen

The products involved in the deal generate about $400 million in annual revenue.

WHITEHOUSE STATION, N.J. (AP) -- Merck & Co. will receive at least $600 million in a deal with Japanese drugmaker Santen Pharmaceutical Co. Ltd. for the purchase of Merck eye care products in several markets.

The Whitehouse Station, N.J., drugmaker said Tuesday the deal was another step in its push to sharpen its commercial focus. Merck also recently announced that it had agreed to sell its consumer health business to Germany's Bayer AG for $14.2 billion. That includes Claritin allergy pills, Coppertone sun care line, and Dr. Scholl's foot care products.

In the latest deal, Merck signed an agreement for Santen to purchase Merck ophthalmology products like Cosopt and Timoptic in Japan and several markets in Europe and Asia. Santen will make an upfront payment of about $600 million and more payments based on sales milestones. The products involved in the deal generate about $400 million in annual revenue.

Santen also will buy from Merck ophthalmology products covered in the deal for two to five years.

Merck, which has divested its U.S. ophthalmology business, will still sell those products in Latin America, Canada, Australia and other markets.